Cargando…

Interchangeability and adverse events in originator-rituximab and its biosimilar (CT-P10) among rheumatic patients: a real-life experience

Biosimilars offer cost-effective and safe treatment options both for patients and healthcare systems. CT-P10 is the first biosimilar of rituximab approved in Europe for use in all indications of originator rituximab (oRTX). This study aimed to provide real-life data on treatment changes and adverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bahap-Kara, Melda, Duran, Emine, Bayraktar-Ekincioglu, Aygin, Karadag, Omer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Im - Original
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951838/ https://www.ncbi.nlm.nih.gov/pubmed/36826744 http://dx.doi.org/10.1007/s11739-023-03222-x

Ejemplares similares

Does information by pharmacists convince the public to get vaccinated for pneumococcal disease and herpes zoster?
por: Bayraktar-Ekincioglu, Aygin, et al.
Publicado: (2021)

The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients
por: Ozdemir, Nesligul, et al.
Publicado: (2021)

The Automatic Substitution of Biosimilars: Definitions of Interchangeability are not Interchangeable
por: Afzali, Anita, et al.
Publicado: (2021)

Benefit versus toxicity risk of digoxin in patients with COVID-19
por: Kelleci Cakir, Burcu, et al.
Publicado: (2022)

Knowledge, attitudes, and practices regarding vaccination among community pharmacists
por: Ozdemir, Nesligul, et al.
Publicado: (2022)

Prevalence of coronavirus disease 2019 in rheumatic patients and evaluation of the effect of disease-modifying anti-rheumatic drugs
por: Moradi, Soroush, et al.
Publicado: (2020)

Focus on biosimilar etanercept – bioequivalence and interchangeability
por: Cantini, Fabrizio, et al.
Publicado: (2018)

Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)

Interchangeability of Biosimilars: Overcoming the Final Hurdles
por: Barbier, Liese, et al.
Publicado: (2021)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
por: Nakagawa, Tomoo, et al.
Publicado: (2019)

Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability
por: White, John, et al.
Publicado: (2018)

Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?
por: Alvarez, Daniel F., et al.
Publicado: (2020)

Biosimilarity and Interchangeability: Principles and Evidence: A Systematic Review
por: McKinnon, Ross A., et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
por: Visser, Jan, et al.
Publicado: (2013)

Fighting on two fronts: drug–drug interactions in people living with HIV infected with SARS-CoV-2
por: Bahap, Melda, et al.
Publicado: (2021)

Assessment of Clinically Relevant Drug Interactions by Online Programs in Renal Transplant Recipients
por: Tecen-Yucel, Kamer, et al.
Publicado: (2020)

Adverse drug reactions in the era of COVID-19
por: Cornelius, Angela P.
Publicado: (2021)

Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
por: Kwon, Hyeok Chan, et al.
Publicado: (2020)

Biosimilars Have Arrived: Rituximab
por: Greenwald, Maria, et al.
Publicado: (2018)

Handgrip strength is associated with adverse outcomes in patients hospitalized for COVID-19-associated pneumonia
por: Pucci, Giacomo, et al.
Publicado: (2022)

Impact of pharmacist-led educational intervention on pneumococcal vaccination rates in cancer patients: a randomized controlled study
por: Ozdemir, Nesligul, et al.
Publicado: (2023)

Associations between CT pulmonary opacity score on admission and clinical characteristics and outcomes in patients with COVID-19
por: Luo, Huanyuan, et al.
Publicado: (2021)

Lung ultrasound in the follow-up of severe COVID-19 pneumonia: six months evaluation and comparison with CT
por: Russo, Giulia, et al.
Publicado: (2022)

Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug–drug interactions
por: Crescioli, Giada, et al.
Publicado: (2020)

CT score in COVID-19-related pneumonia, the radiologist, and the internist. Trying to unmask who is “the good”, who is “the bad” and who is “the ugly”
por: Crisci, Giulia, et al.
Publicado: (2021)

The role of exhaled nitric oxide (FeNO) in the evaluation of lung parenchymal involvement in COVID-19 patients
por: Kerget, Buğra, et al.
Publicado: (2022)

Biologicals and Biosimilars in Hematology: The Case of Rituximab
por: Vulto, Arnold G.
Publicado: (2019)

Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution
por: Druedahl, Louise C., et al.
Publicado: (2022)

Can lung ultrasound replace CT scan in a 6-month follow-up of severe COVID-19 pneumonia? A brief commentary
por: Porzio, Marianna, et al.
Publicado: (2023)

A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability
por: Becciolini, Andrea, et al.
Publicado: (2017)

Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
por: Lee, Kyoung Hoon, et al.
Publicado: (2018)

Knowledge, Attitude, and Practice Towards Biosimilars and Interchangeable Products: A Prescriptive Insight by the Pharmacists
por: Shakeel, Sadia, et al.
Publicado: (2020)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Rituximab biosimilars open new horizons in immunotherapy
por: Jaeger, Ulrich
Publicado: (2017)

Efficacy and safety of rituximab biosimilar in refractory lupus
por: Pongtarakulpanit, Nantakarn, et al.
Publicado: (2020)

Introduction of Biosimilar Rituximab: A Hospital Perspective
por: Cheesman, Simon
Publicado: (2020)

Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting
por: Pavlych, Viktoriya, et al.
Publicado: (2020)

Safety of switching between rituximab biosimilars in onco-hematology
por: Urru, Silvana A. M., et al.
Publicado: (2021)

Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease
por: van Dijk, A. M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_642kq6vb8rrqk6e77ca7eimlmn